Home Proteases -Epigenetics -Metabolism PAD

PAD

Isoform-selective Products

PAD Products

  • All (5)
  • PAD Inhibitors (5)
  • New PAD Products
Catalog No. Product Name Information Product Use Citations Product Validations
S8141 Cl-amidine Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor with IC50 values of 5.9 ± 0.3 μM, 0.8 ± 0.3 μM, 6.2 ± 1.0 μM for PAD4, PAD1 and PAD3, respectively. Cl-amidine induces apoptosis.
Nat Commun, 2024, 15(1):8663
Diabetes, 2024, db231000
Heliyon, 2024, 10(1):e23633
S7803 GSK484 HCl GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.
Eur J Pharmacol, 2024, S0014-2999(24)00322-4
Cell Discov, 2023, 9(1):104
Cell Discov, 2023, 9(1):104
S9644 BMS-P5 BMS-P5, a potent selective pharmacological inhibitor of PAD4, is used to evaluate the effect of PAD4 inhibition on multiple myeloma (MM)-induced neutrophil extracellular trap (NET) formation.
E4995New Cl-amidine hydrochloride Cl-amidine hydrochloride is an inhibitor of pan-peptidylarginine deiminase (PAD), with an IC50 of 0.8 µM, 6.2 µM, and 5.9 µM for PAD1, PAD3, and PAD4, respectively.
S7802New GSK199 GSK199 is a reversible, specific inhibitor of peptidyl arginine deiminase 4 (PAD4), with an IC50 of 200 nM without calcium. It is involved in histone citrullination and neutrophil extracellular trap formation, making it useful for studying autoimmune, cardiovascular, and oncological diseases.
S8141 Cl-amidine Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor with IC50 values of 5.9 ± 0.3 μM, 0.8 ± 0.3 μM, 6.2 ± 1.0 μM for PAD4, PAD1 and PAD3, respectively. Cl-amidine induces apoptosis.
Nat Commun, 2024, 15(1):8663
Diabetes, 2024, db231000
Heliyon, 2024, 10(1):e23633
S7803 GSK484 HCl GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.
Eur J Pharmacol, 2024, S0014-2999(24)00322-4
Cell Discov, 2023, 9(1):104
Cell Discov, 2023, 9(1):104
S9644 BMS-P5 BMS-P5, a potent selective pharmacological inhibitor of PAD4, is used to evaluate the effect of PAD4 inhibition on multiple myeloma (MM)-induced neutrophil extracellular trap (NET) formation.
E4995New Cl-amidine hydrochloride Cl-amidine hydrochloride is an inhibitor of pan-peptidylarginine deiminase (PAD), with an IC50 of 0.8 µM, 6.2 µM, and 5.9 µM for PAD1, PAD3, and PAD4, respectively.
S7802New GSK199 GSK199 is a reversible, specific inhibitor of peptidyl arginine deiminase 4 (PAD4), with an IC50 of 200 nM without calcium. It is involved in histone citrullination and neutrophil extracellular trap formation, making it useful for studying autoimmune, cardiovascular, and oncological diseases.
E4995New Cl-amidine hydrochloride Cl-amidine hydrochloride is an inhibitor of pan-peptidylarginine deiminase (PAD), with an IC50 of 0.8 µM, 6.2 µM, and 5.9 µM for PAD1, PAD3, and PAD4, respectively.
S7802New GSK199 GSK199 is a reversible, specific inhibitor of peptidyl arginine deiminase 4 (PAD4), with an IC50 of 200 nM without calcium. It is involved in histone citrullination and neutrophil extracellular trap formation, making it useful for studying autoimmune, cardiovascular, and oncological diseases.

Choose Selective PAD Inhibitors

Tags: PAD inhibitor|PAD agonist|PAD activator|PAD inducer|PAD antagonist|PAD signaling pathway|PAD assay kit